Avalo Therapeutics (AVTX) Other Non-Current Liabilities (2015 - 2025)
Avalo Therapeutics (AVTX) posted Other Non-Current Liabilities of $35000.0 for Q4 2025, down 99.85% on a QoQ basis from $23.2 million in Q3 2025, and down 99.59% year-over-year from $8.5 million in Q4 2024.
Avalo Therapeutics (AVTX) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
Avalo Therapeutics' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $35000.0 for Q4 2025.
- Quarterly Other Non-Current Liabilities fell 99.59% year-over-year to $35000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35000.0 (down 99.59% YoY) and the FY2025 annual result came in at $35000.0, down 99.59% from the prior year.
- Other Non-Current Liabilities was $35000.0 for Q4 2025 at Avalo Therapeutics, down from $23.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $23.2 million in Q3 2025 and bottomed at $35000.0 in Q4 2025.
- A 5-year average of $5.5 million and a median of $2.4 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 711.13% — and 2025, when it sank 99.59%.
- Avalo Therapeutics' Other Non-Current Liabilities stood at $1.4 million in 2021, then surged by 245.99% to $4.8 million in 2022, then grew by 14.91% to $5.6 million in 2023, then jumped by 52.79% to $8.5 million in 2024, then sank by 99.59% to $35000.0 in 2025.
- Business Quant data shows AVTX's Other Non-Current Liabilities at $35000.0 in Q4 2025, $23.2 million in Q3 2025, and $10.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35,000.00 |
| Sep 30, 2025 | 23.16 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 7.74 Mn |
| Dec 31, 2024 | 8.48 Mn |
| Sep 30, 2024 | 11.81 Mn |
| Jun 30, 2024 | 10.71 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 1.54 Mn |
| Mar 31, 2023 | 1.63 Mn |
| Dec 31, 2022 | 4.83 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 1.94 Mn |
| Mar 31, 2022 | 2.36 Mn |
| Sep 30, 2021 | 1.40 Mn |
| Jun 30, 2021 | 1.56 Mn |
| Mar 31, 2021 | 1.72 Mn |
| Dec 31, 2020 | 1.88 Mn |